ArticleFrontiers in oncology2025
Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastasis of prostate adenocarcinoma is exceedingly rare, accounting for less than 1% of all skin metastases. It typically occurs late in the disease course and often mimics benign or primary skin malignancies. An elderly man with a history of benign prostatic hypertrophy presented for a routine dermatologic examination, during which an ulcerated nodule was identified on his upper back. Histopathology of the lesion revealed a dermal-based malignant glandular tumor. Immunohistochemistry was negative for CK20, CK5/6, PAX-8, TTF-1, PSA, and PIN4, but positive for PSAP and NKX3.1, consistent with mucin-producing prostate adenocarcinoma. Although his recent digital rectal exam was normal and prostate cancer screening had been deferred due to age, further work-up showed elevated serum PSA (30.49 ng/mL) and widespread metastatic disease on PET/CT imaging. He was started on androgen deprivation therapy with relugolix. This case underscores the diagnostic importance of skin biopsies in evaluating atypical lesions and highlights a rare presentation of metastatic prostate adenocarcinoma in an elderly patient with minimal systemic symptoms. It also raises awareness of prostate cancer presenting as solitary cutaneous metastasis and calls attention to the potential value of PSA screening in select elderly patients. Recognizing uncommon cutaneous manifestations may lead to earlier diagnosis and improved management of advanced internal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.